Loading clinical trials...

Apatinib for Resectable Colorectal Cancer | Clinical Trials | Clareo Health

WITHDRAWNNA

Apatinib for Resectable Colorectal Cancer

Apatinib With Postoperative Adjuvant Chemotherapy for Operable Colorectal Cancer

NCT03228043•Nanchong Central Hospital

Summary

Objective: To compare the outcome of patients with colorectal cancer who treated with adjuvant therapy or Apatinib with adjuvant therapy postoperatively. Language: English.

Eligibility

Age

18 - 75 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. ECOG performance status score: 0-1.
•2. All colorectal cancer patients underwent curative intent surgery
•3. Patients in stage Ⅱ(Any T, N0, M0) with multiple high-risk factors or stage Ⅲ (any T, N1-2, M0) which confirmed by pathology.
•4. Patients who did not receive other treatments for colorectal adenocarcinoma after surgery;
•5. The main organ function is good, patients must meet the following requirements with 14 days before using Apatinib:
•* blood routine examination:
•* hemoglobin\> 90 g / L (14 days without blood transfusion);
•* neutrophil count\> 1.5 x 109 / L;
•* platelet count\> 100 × 109 / L;
•* biochemical examination:
+7 more criteria

Exclusion Criteria

•1. Patients with other malignancies, except for cured skin basal cell carcinoma and cervical cancer in situ.
•2. Participated in other drug clinical trials within four weeks.
•3. Have a variety of factors that affect oral medication (such as unable to swallow, chronic diarrhea and intestinal obstruction, etc.).
•4. Have a history of bleeding, screening within 4 weeks before any serious grade to CTCAE4.0 3 degrees or more bleeding events.
•5. Patients with central nervous system metastases or a history of central nervous system metastases before screening. For patients with suspected central nervous system metastases, CT or MRI examinations must be performed within 28 days prior to randomization to exclude central nervous system metastasis.
•6. History of high blood pressure can not be controlled with a single antihypertensive drug therapy (With a systolic blood pressure\> 140 mmHg, diastolic blood pressure\> 90 mmHg. A history of unstable angina within 3 months or a new diagnosis of angina within 6 months (Including QTcF: male ≥ 450 ms, female ≥470 ms) required long-term use of antiarrhythmic drugs and New York Heart Association classification ≥ Class II cardiac insufficiency.
•7. Urinary protein ≥ ++ and urine protein\> 1.0 g in 24 hours.
•8. Patients with anastomotic fistula, pancreatic fistula or anastomotic stenosis and other serious postoperative complications.
•9. Long-term non-healing wounds or bone fractures.
•10. history of organ transplantation.
+7 more criteria

Locations (1)

Yunhong Tian

Nanchong, Sichuan, China

Key Dates

Start Date

March 1, 2020

Primary Completion Date

March 1, 2021

Completion Date

March 1, 2023

Last Updated

November 14, 2024

Conditions

ApatinibOutcome, FatalColorectal CancerSurgeryAdjuvant Chemotherapy

Interventions

Apatinib

DRUG

CAPEOX

DRUG

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

NCT04704661

Advanced Breast CarcinomaAdvanced Colon Carcinoma+38 more

View study

RECRUITINGPHASE1

Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer

NCT06696768

Metastatic Colorectal AdenocarcinomaStage III Colorectal Cancer AJCC v8+2 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: November 14, 2024Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Apatinib for Resectable Colorectal Cancer

Inclusion Criteria

Exclusion Criteria

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer

Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Colorectal Cancer w/Liver Dominant Disease